Half-year report · Q2
4272.TEDINET S100UPTW
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥109.1bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥201.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥97.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥11.2bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥11.7bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥12.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥8.6bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥6.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥6.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥356.6bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥363.2bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥349.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥92.4bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥92.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥264.2bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥270.5bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥267.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥50.7bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥56.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥52.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥64.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥57.2bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥53.1bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥14.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥23.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥16.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥19.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥12.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥9.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥3.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥36.21 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.8 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.74 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥36.2 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.79 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥36.72 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 73.8% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 76.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥87m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥4.4bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥32.7bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥32.6bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.0bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥7.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥109.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥109.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥87m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥15.5bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥78m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥78m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥3.9bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥28.0bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥27.9bn |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥77m |
| jpcrp040300-q2r_E00836-000Fine Chemicals Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.5bn |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E00836-000Life Science Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥39.5bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥39.5bn |
| jpcrp040300-q2r_E00836-000Mobility And Imaging Business Unitreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥98.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥97.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥78m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 576
| Item | Context | Value | Unit |
|---|---|---|---|
| Payrolls general and administrative expenses | CurrentYTDDuration | 2362000000 | JPY |
| Bonuses and allowance general and administrative expenses | Prior1YTDDuration | 448000000 | JPY |
| Bonuses and allowance general and administrative expenses | CurrentYTDDuration | 509000000 | JPY |
| Retirement benefit expenses ga | Prior1YTDDuration | 92000000 | JPY |
| Retirement benefit expenses ga | CurrentYTDDuration | 90000000 | JPY |
| Depreciation ga | Prior1YTDDuration | 359000000 | JPY |
| Depreciation ga | CurrentYTDDuration | 381000000 | JPY |
| Research and development expenses sga | Prior1YTDDuration | 6974000000 | JPY |
| Research and development expenses sga | CurrentYTDDuration | 6327000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 39467000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 27943000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30497000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 97908000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 97908000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 77000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 78000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -78000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 39467000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 28021000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30498000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 97987000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -78000000 | JPY |
| Net sales | Prior1YTDDuration | 97908000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 3318000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 2254000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 3087000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 8660000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -3892000000 | JPY |
| Operating income | Prior1YTDDuration | 4767000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 45996000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 32618000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30495000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 109109000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 109109000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 87000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 0 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 87000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -87000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00836-000MobilityAndImagingBusinessUnitReportableSegmentMember | 45996000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00836-000FineChemicalsBusinessUnitReportableSegmentMember | 32705000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00836-000LifeScienceBusinessUnitReportableSegmentMember | 30495000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 109196000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -87000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |